Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cell vaccine for melanoma
- Development stage
- Unknown
- Lead developer
- Froceth
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
The autologous dendritic cell vaccine for melanoma is a personalized cancer immunotherapy developed by Froceth. This therapy utilizes a patient's own dendritic cells (DCs), which are matured and modulated—specifically using exosome-based immunomodulation in Froceth's approach—to enhance their ability to present melanoma-specific antigens. Once re-administered to the patient, typically via intradermal injection, these activated dendritic cells stimulate a targeted T-cell response against melanoma cells. Froceth's dendritic cell platform, designated as DLP (Dendritic Cell Preparation), is currently in preclinical development for melanoma, while related DC-based programs are being investigated for other indications such as kidney cancer, prostate cancer, and ovarian cancer.
- Other names
- Dendritic Cell PreparationExosome-modulated autologous DC vaccineautologous dendritic cell vaccine
02
Targets
γδ TCR (T-cell receptor)GD3 (Ganglioside GD3)
Beyond the preview
Go deeper on autologous dendritic cell vaccine for melanoma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cell vaccine for melanoma.